<DOC>
	<DOCNO>NCT01029418</DOCNO>
	<brief_summary>This phase I/II clinical trial test combination sorafenib AZD6244 advance hepatocellular carcinoma Childs A liver cirrhosis . The aim phase I portion determine appropriate dose drug combination . The phase 2 study look effectiveness safety drug combination</brief_summary>
	<brief_title>AZD6244 Sorafenib Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>Patients unresectable BCLC Stage B/C hepatocellular carcinoma biopsy-proven ( histology cytology prior tumor biopsy specimen acceptable Patients without prior systemic treatment ( chemotherapy molecular target therapy ) except prior adjuvant therapy , give 6 month ago Child-Pugh class A ECOG performance status 0 1</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients unresectable BCLC Stage B/C hepatocellular carcinoma biopsyproven ( histology cytology prior tumor biopsy specimen acceptable ) Patients without prior systemic treatment ( chemotherapy molecular target therapy ) except prior adjuvant therapy , give 6 month ago Patients prior local therapy ( TACE ; PEI ; RFA ) 4 week prior study entry No radiotherapy within 4 week entry ChildPugh class A ( Appendix A ) Age 21 year old ECOG performance status 0 1 ( Appendix A ) Life expectancy &gt; 3 month . Patients must normal organ marrow function define : Absolute neutrophil count &gt; 1.5 x 109/L ; Platelets &gt; 75 x 109/L ; Haemoglobin &gt; 9.0g/dl ; Total bilirubin &lt; 51umol/L ( 3 mg /dL ) ; AST ( SGOT ) /ALT ( SGPT ) &lt; 5 X institutional ULN ; Creatinine 1.5 ULN ; INR &lt; 1.7 prothrombin time ( PT ) &lt; 4 second ULN ; Left ventricular ejection fraction ( LVEF ) &gt; 50 % Measurable disease accord RECIST . A lesion previously locally treat ( include TACE RFA ) eligible long evidence disease progression Suitable oral administration drug Ability understand willingness sign write informed consent document Prior systemic therapy include sorafenib MEK inhibitor sunitinib investigational drug Any prior local therapy ( surgery , radiation therapy , hepatic arterial embolization , cryoablation ) within 4 week study entry . Prior liver transplant NCI CTCAE grade &gt; 3 hemorrhage within 4 week start study treatment , document variceal hemorrhage grade within 12 month study entry ( document endoscopy ) Presence esophageal varix ( &gt; Grade 2 ) risk bleed and/or serious nonhealing wound/ulcer ( document endoscopy ) History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 28 day study entry Patients underlie inflammatory bowel disease , partial complete bowel obstruction chronic diarrhea Any follow within 12 month prior study drug administration : severe/unstable angina , myocardial infarction , coronary artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident , include transient ischemic attack , pulmonary embolism . History cardiac disease : active congestive heart failure cardiac arrythmias NCI CTCAE grade &gt; 2 require pacemaker uncontrolled hypertension cardiomyopathy atrial fibrillation rate &gt; 100bpm Patients factor increase risk QT prolongation arrhythmic event ( hypokalemia , family history long QT interval syndrome ) QTc interval &gt; 450ms male &gt; 470ms female screen</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>HCC</keyword>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>liver cancer</keyword>
</DOC>